News & Updates
Filter by Specialty:
Show Multimedia Only

Semaglutide 2.4 mg gets US FDA approval for MASH
a day ago
byChristina Lau
Subcutaneous (SC) semaglutide 2.4 mg QW is recently granted accelerated approval by the US FDA for treatment of metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.